Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CFI-402257 + Paclitaxel in Advanced/Metastatic HER2-Negative Breast Cancer
NCT03568422Phase 2Active, not recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Feb 2019
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of luvixasertib in breast cancer, sponsored by Canadian Cancer Trials Group. Started Feb 2019; status: active, not recruiting.
02
Drugs
luvixasertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03568422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03568422.